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Abstract
The effectiveness of many DNA-damaging chemotherapeutic drugs depends on their ability to form monoadducts, intrastrand 
crosslinks and/or interstrand crosslinks (ICLs) that interfere with transcription and replication. The ERCC1–XPF endonu-
clease plays a critical role in removal of these lesions by incising DNA either as part of nucleotide excision repair (NER) or 
interstrand crosslink repair (ICLR). Engagement of ERCC1–XPF in NER is well characterized and is facilitated by binding 
to the XPA protein. However, ERCC1–XPF recruitment to ICLs is less well understood. Moreover, specific mutations in XPF 
have been found to disrupt its function in ICLR but not in NER, but whether this involves differences in lesion targeting is 
unknown. Here, we imaged GFP-tagged ERCC1, XPF and ICLR-defective XPF mutants to investigate how in human cells 
ERCC1–XPF is localized to different types of psoralen-induced DNA lesions, repaired by either NER or ICLR. Our results 
confirm its dependence on XPA in NER and furthermore show that its engagement in ICLR is dependent on FANCD2. 
Interestingly, we find that two ICLR-defective XPF mutants (R689S and S786F) are less well recruited to ICLs. These stud-
ies highlight the differential mechanisms that regulate ERCC1–XPF activity in DNA repair.
Keywords DNA damage response · Fanconi anemia · DNA repair · Xeroderma pigmentosum–Cockayne syndrome 
complex
Introduction
The heterodimeric ERCC1–XPF complex (also called 
ERCC1–ERCC4) is a structure-specific endonuclease that 
plays an essential role in multiple DNA repair pathways 
by incising DNA repair intermediate fork structures at the 
junction between single-stranded and double-stranded DNA. 
ERCC1–XPF excises bulky DNA lesions in nucleotide 
excision repair (NER) [1], unhooks interstrand crosslinks 
(ICLs), i.e., covalent linkages between two bases on opposite 
DNA strands, in interstrand crosslink repair (ICLR) [2–4], 
removes 3′ flaps of DNA intermediate structures in specific 
double-strand break (DBS) repair pathways [5] and cleaves 
3′ overhangs from uncapped telomeres to shorten them [6]. 
Hereditary mutations in ERCC1–XPF cause several distinct 
human syndromes characterized by either (skin) cancer 
proneness, i.e., xeroderma pigmentosum (XP), developmen-
tal abnormalities and accelerated aging, i.e., XP combined 
with Cockayne syndrome (XPCS complex), or bone marrow 
failure and chromosome fragility, i.e., Fanconi anemia (FA) 
[1, 7–10]. The severe and pleiotropic symptoms associated 
with these syndromes highlight the fundamental role of the 
complex in promoting health by its essential role in different 
DNA repair processes.
The ERCC1–XPF complex was initially identified as an 
essential endonuclease in NER [1]. This DNA repair path-
way removes many different types of DNA lesions that dis-
rupt base-pairing, including photolesions induced by UV 
light and monoadducts and intrastrand crosslinks induced by 
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widely used chemotherapeutic drugs such as mitomycin C 
(MMC), cisplatin and psoralens [11, 12]. NER is a multistep 
process consisting of the coordinated, sequential assembly 
of multiple repair enzymes guided by direct protein–protein 
and protein–DNA interactions. NER is initiated by two dif-
ferent damage sensing mechanisms. In global genome NER 
(GG-NER), lesions located anywhere in the genome are 
recognized by the UV-DDB and XPC–RAD23B–CETN2 
complexes. In transcription-coupled NER, lesions located 
in the transcribed strand are sensed by stalling of elongating 
RNA polymerase II, which leads to the recruitment of the 
CSA, CSB and UVSSA proteins. Lesion recognition in both 
subpathways is followed by recruitment of the transcription 
factor TFIIH, which unwinds the DNA and verifies the pres-
ence of damage. TFIIH function is stimulated by the DNA 
damage-binding protein XPA [13], which together with the 
single-stranded DNA-binding protein RPA coordinates the 
positioning of the endonucleases ERCC1–XPF and XPG. 
XPG is first recruited through an interaction with TFIIH 
[14]. Next, ERCC1–XPF is recruited through a direct inter-
action between XPA and an XPA-binding region located 
within the central domain of ERCC1 [15–19]. XPF is the 
actual nuclease of this complex and incises the DNA 5′ to 
the lesion [20], after which XPG incises the DNA 3′ of the 
lesion. Following excision, the resulting 22–30 nt gap is 
filled by DNA synthesis and ligation.
In addition to NER, ERCC1–XPF is essential for the 
removal of ICLs. These are rare DNA modifications induced 
by either endogenous aldehydes [21] or by chemotherapeutic 
drugs such as MMC, cisplatin and psoralens [22]. ICLs are 
highly cytotoxic as they obstruct DNA strand separation, 
required for both replication and transcription. However, 
despite many studies focused on understanding how ICLs are 
removed from the genome, the molecular mechanism(s) of 
ICLR is not yet entirely clear. ICLR is a multistep, sequential 
assembly of repair enzymes and involves distinct subpath-
ways depending on the cell cycle phase and type of ICL. 
Most ICLs are repaired during S phase, which requires the 
concerted action of different DNA repair systems, including 
the Fanconi anemia (FA) and homologous recombination 
(HR) repair pathways, NER and translesion synthesis (TLS). 
This replication-dependent ICLR is proposed to be initiated 
when two replication forks converge on an ICL. This leads 
to the helicase heterodimer FANCM/FAAP24-dependent 
recruitment of the FA-core complex and monoubiquitylation 
of the FANCD2–FANCI heterodimer [23, 24]. Experiments 
using Xenopus laevis egg extract and in vitro-modeled ICL-
containing replication structures suggest that ERCC1–XPF 
is then recruited, depending on its interaction with the scaf-
fold protein SLX4 that stimulates its function [2, 25, 26]. 
ERCC1–XPF incises the lagging strand to unhook the ICL, 
possibly together with another endonuclease or together with 
the exonuclease SNM1A that digests past the ICL [27]. The 
resulting single-stranded gap is filled by TLS and is used 
as homology template for repair of the remaining double-
strand break by HR [28, 29]. The unhooked crosslink is 
likely repaired by NER. Certain types of ICLs, such as, for 
instance, induced by psoralens, appear to be preferentially 
unhooked by DNA glycosylase NEIL3-mediated cleavage 
of one of the two N-glycosyl bonds forming the crosslink, 
which circumvents the need for FA factors and incision of 
the DNA backbone [30]. Other forms of ICLR probably 
exist that are independent of replication, such as in slowly 
or nonreplicating cells, but these are only poorly understood. 
Replication-independent ICLR is proposed to involve GG-
NER and/or TC-NER factors, likely depending on the type 
of crosslinked chemical, including ERCC1–XPF to unhook 
the ICL [31–35]. TLS then fills the resulting gap while a 
second round of NER removes the remaining ICL from the 
opposite DNA strand [22, 28].
Understanding how ERCC1–XPF is recruited to sites of 
DNA damage is necessary to understand how ERCC1–XPF 
protects against different types of DNA damage, including 
those induced by commonly used chemotherapeutics, how 
it helps to prevent cancer and how its inherited deficiency 
can cause different diseases. Previous imaging studies by 
us and others have highlighted the importance of XPA in 
regulating ERCC1–XPF recruitment to UV damage and have 
shown that patient-derived mutations within XPF can dif-
ferentially affect its subcellular localization or recruitment 
to UV-induced DNA damage, explaining phenotypic differ-
ences observed in diseases associated with NER dysfunc-
tion, such as XP and XPCS complex [16, 17, 36, 37]. How-
ever, XPA is not implicated in replication-dependent ICLR 
and not much is known about how ERCC1–XPF is recruited 
to ICLs in human cells. Here we used imaging of wild-type 
and ICLR-defective XPF to investigate how ERCC1–XPF is 
distinctly recruited to psoralen–DNA crosslinks repaired by 
NER or by ICLR. Our results substantiate that FANCD2 is 
required for recruitment of the complex to ICLs and suggest 
that XPF ICLR-defective mutants are unable to efficiently 
associate with ICLs.
Methods
Cell culture and siRNA
U2OS cells expressing ERCC1–GFP, XPF–GFP and XPF-
C236R, XPF-R689S and XPF-S786F were previously 
described [37, 38]. To knockout XPA, U2OS cells express-
ing ERCC1–GFP or XPF–GFP were transfected with pLen-
tiCRISPR-V2 plasmid [39] encoding the sgRNA GGC GGC 
TTT AGA GCA ACC CG, targeting the first exon of the XPA 
gene. Transfected cells were selected with puromycin and 
individual XPA KO clones were screened by immunoblot 
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and sequencing and analyzed using Tracking Indels by 
DEcomposition as described [40]. All cell lines were cul-
tured in standard condition: DMEM/F10 supplemented with 
10% fetal calf serum (FCS) and 1% penicillin–streptomy-
cin (PS) at 37 °C and 5%  CO2. For siRNA treatment, cells 
were transfected using RNAiMax (Invitrogen) with control 
siRNA (Dharmacon, D-001210-05), siRNA targeting XPA 
(Dharmacon, MJAWM-000011) or FANCD2 (Dharmacon, 
D-016376-02), 48 h before UVC or 8-MOP treatment.
Immunoprecipitation
Immunoprecipitation of chromatin-enriched nuclear extracts 
for mass spectrometry was performed as described [41]. 
ERCC1–GFP cells were seeded in 14-cm culture dishes 
and irradiated with 20 J/m2 UVC (254 nm lamp, Philips) 
or left untreated. After 1 h, cells were harvested by scrap-
ing in 3 ml cold PBS containing protease inhibitor cocktail 
(Roche), centrifuged for 10 min at 1500 rpm and washed 
again with PBS. Cell pellet was then incubated in HEPES 
buffer (10 mM HEPES, pH 7.6, 1.5 mM  MgCl2, 10 mM KCl, 
0.5 mM DTT, protease inhibitor cocktail) for 10 min on ice. 
Dounce homogenizer with a type A pestle was used to iso-
late the nuclei prior to centrifugation at 3000 rpm for 10 min 
at 4 °C. Next, cell pellets were resuspended in HEPES buffer 
(100 mM HEPES, pH 7.6, 1.5 mM  MgCl2, 150 mM NaCl, 
0.5 mM DTT, 25% glycerol, protease inhibitor cocktail) and 
subsequently dounced using a type B pestle. 25 U micrococ-
cal nuclease (MNase, Sigma) was used to digest chromatin 
extracts for 1 h at 4 °C to obtain mononucleosomal size 
material by centrifugation at 15,000 rpm for 15 min.
Immunoprecipitation of benzonase-treated lysates was 
performed as described [42]. Briefly, cells were lysed using 
IP buffer (30 mM Tris, pH 7.5, 150 mM NaCl, 2 mM MgCl2, 
0.5% Triton X-100, protease inhibitor cocktail (Roche)) sup-
plemented with 250 U/mL  Benzonase® nuclease.
In both cases, GFP-Trap®_A beads (Chromotek) were 
used to immunoprecipitate GFP-tagged proteins. Cell lysate 
and immunoprecipitated samples were analyzed by immu-
noblot or mass spectrometry. For mass spectrometry, beads 
from UVC- and mock-treated cells were combined in a 1:1 
ratio and label swapping was used to validate the biological 
findings and exclude contaminants.
Immunoblot
Protein lysates were prepared by scraping cells in 2 × sam-
ple buffer (125 mM Tris–HCl, pH 6.8, 20% glycerol, 10% 
2-β-mercaptoethanol, 4% SDS, 0.01% bromophenol blue) 
and boiled at 98 °C for 5 min. Proteins were separated by 
SDS-PAGE and transferred to a PVDF membrane (0.45 µm, 
Merck Millipore). Subsequently, membranes were blocked 
in 2% BSA and incubated with primary antibodies and 
secondary antibodies conjugated with CF IRDye 680 and 
770 (Sigma) for 1 h or overnight. Primary antibodies used 
were anti-XPA (sc-853, Santa Cruz Biotechnology), anti-
SNF2H (ab3749, Abcam), anti-Tubulin (T6074, Sigma), 
anti-FANCD2 (nb100-316, Novus Biologicals), anti-GFP 
(ab290, Abcam), anti-SLX4 (NBP1-28680, Novus Biologi-
cals), anti-ERCC1 (ab129267, Abcam), anti-H2B (07-371, 
Millipore), and anti-RPA70 (2267, Cell signaling). Second-
ary antibodies were visualized using the Odyssey CLx Infra-
red Imaging System (LI-COR Biosciences).
Clonogenic survival assays
To analyze the UV sensitivity of the ERCC1–GFP and 
XPF–GFP XPA-deficient cells, we seeded 500 cells in six-
well plates in triplicate. After 24 h, cells were irradiated with 
the indicated doses of UV (254 nm UVC lamp, Philips). 
5–7 days after irradiation, cells were fixed and stained with 
50% methanol, 7% acetic acid, and 0.1% Brilliant Blue R 
(Sigma). Colonies were counted using the integrated col-
ony counter GelCount (Oxford Optronix). The number of 
colonies in the non-treated cells was set to 100% and the 
number of colonies after UV treatment was normalized to 
the number of colonies in untreated samples and plotted as 
percentage survival.
UV, psoralen treatment and immunofluorescence
To analyze the localization of proteins to LUD, cells seeded 
on coverslips were irradiated with 60 J/m2 (254 nm UVC 
lamp, Philips) through an 8-µm microporous filter (Milli-
pore) and fixed with 2% paraformaldehyde supplemented 
with 0.1% Triton X-100, 1 h after irradiation. Next, cells 
were permeabilized with 0.1% Triton X-100 for 20 min, 
incubated with 0.07 M NaOH for 5 min (to visualize CPDs) 
and washed in PBS containing 0.15% glycine and 0.5% BSA 
before proceeding with immunofluorescence. Analysis of 
protein localization to psoralen-induced DNA damage was 
performed as described [43, 44]. Briefly, cells were seeded 
on coverslips and incubated with 50 µM 8-methoxypsoralen 
(8-MOP, Sigma) for 2 h. 8-MOP was locally activated in 
stripes along the cell nuclei by a 355-nm UVA laser coupled 
to a PALM laser dissection microscope (Zeiss) through a 
40 × 0.60 NA Korr LD Plan Neofluar objective. Cells were 
then fixed with 2% paraformaldehyde supplemented with 
0.1% Triton X-100 and washed in PBS containing 0.15% 
glycine and 0.5% BSA before proceeding with immuno-
fluorescence. For immunofluorescence, cells were stained 
with primary antibodies for 2 h and then incubated with 
secondary antibodies conjugated to ALEXA fluorochromes 
488, 555 and 633 (Invitrogen) for 1 h. Primary antibod-
ies used were against: GFP (ab290, Abcam), CPD (CAC-
NM-DND-001; Cosmo Bio), XPA (sc-853, Santa Cruz 
 M. Sabatella et al.
1 3
Biotechnology), FANCD2 (nb100-316, Novus Biologicals), 
SLX4 (NBP1-28680, Novus Biologicals), γH2AX (ab11174, 
Abcam or 05-636, Millipore), XPF (sc-136153, Santa Cruz 
Biotechnology). DAPI Vectashield (Vector Laboratories) 
was used to mount the coverslips. Cells were imaged using 
an LSM700 microscope equipped with a 40 × Plan-apochro-
mat 1.3 NA oil immersion lens (Carl Zeiss). The software 
Image J was used to quantify fluorescence intensity. Fold 
accumulation was calculated as the ratio between fluores-
cence intensity at the site of damage and fluorescence inten-
sity in the cell nucleus, measured in at least 60 cells per 
condition in two or more separate experiments. Statistical 
analysis of the differences in GFP intensity at sites of local 
damage was performed using an unpaired two-tailed Stu-
dent’s t test.
SILAC‑based mass spectrometry analysis
For SILAC, cells were cultured in DMEM containing 
10% dialyzed FBS (Gibco), 10% GlutaMAX (Life Tech-
nologies), penicillin/streptomycin (Life Technologies), 
unlabeled l-arginine–HCl and l-lysine–HCl (“light”) or 
13C6,15N4l–arginine–HCl and  13C6,15N2l–lysine–2HCl 
(“heavy”) (Cambridge Isotope Laboratories). For the “For-
ward” experiment, immunoprecipitation extracts derived 
from “light”-labeled mock-treated cells were mixed with 
extracts derived from “heavy” UVC-treated (20  J/m2) 
cells; for the “Reverse” experiment, extracts derived from 
“light”-labeled UVC-treated (20 J/m2) cells were mixed 
with extracts derived from “heavy” mock-treated cells. 
After protein separation, SDS-PAGE gel was cut into 2-mm 
slices and subjected to in-gel reduction with dithiothreitol, 
alkylation with iodoacetamide (98%; D4, Cambridge Isotope 
Laboratories) and digested with trypsin (sequencing grade; 
Promega). Samples were analyzed by mass spectrometry 
using an Orbitrap Fusion™ Tribrid™ mass spectrometer 
and EASY-nLC™ 1000 (Thermo). MaxQuant software was 
used to analyze the data.
Results
ERCC1–XPF recruitment to sites of UV damage is XPA 
dependent
To investigate how the activity of ERCC1–XPF in response 
to ICLs is regulated in cells, we studied how the complex is 
recruited to sites of locally induced psoralen-DNA crosslinks 
independently of NER. ERCC1–XPF binding to damaged 
DNA during NER critically depends on its interaction with 
XPA [15–19]. Therefore, we generated XPA-knockout (KO) 
cell lines by transfecting a plasmid encoding Cas9 and an 
sgRNA targeting exon 1 of XPA in previously generated 
U2OS cells expressing ERCC1–GFP [38] and U2OS XPF 
KO cells expressing XPF–GFP [37]. Sequencing and Track-
ing Indels by DEcomposition analysis [40] revealed multiple 
indel mutations in the XPA gene of a selected ERCC1–GFP-
expressing and a selected XPF–GFP-expressing XPA KO 
clone (data not shown). The absence of XPA in these clones 
was confirmed by immunoblot (Fig. 1a, b), while strong UV 
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Fig. 1  Generation of XPA knockout in ERCC1–GFP- and XPF–GFP-
expressing cells. a Immunoblot showing XPA expression levels in 
XPA-proficient and XPA-knockout (XPA KO) U2OS cells expressing 
GFP-tagged ERCC1. SNF2H was used as loading control. b Immu-
noblot showing XPA expression levels in XPA-proficient and XPA-
knockout (XPA KO) U2OS cells expressing GFP-tagged XPF. Tubu-
lin was used as loading control. c Clonogenic UV survival assays of 
wild-type U2OS cells without any transgene (U2OS) and XPA-profi-
cient and XPA KO U2OS cells expressing ERCC1–GFP. Results are 
plotted as average of three independent experiments, each performed 
in triplicate. d Clonogenic UV survival assays of XPA-proficient and 
XPA KO U2OS cells expressing XPF–GFP. Results are plotted as 
average of three independent experiments, each performed in tripli-
cate. In c and d error bars represent the SEM
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hypersensitivity (Fig. 1c, d) showed that these cells indeed 
lack functional NER.
To show the validity of these cells in discerning between 
ERCC1–XPF activities in NER and in ICLR, we tested 
ERCC1–GFP and XPF–GFP recruitment to local UV 
damage (LUD) in XPA-proficient and XPA KO cells by 
immunofluorescence, after UVC irradiation through an 
8-µm microporous filter (Fig. 2a–c). While both ERCC1 
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Fig. 2  XPF recruitment to LUD is XPA dependent. a Immunofluores-
cence images showing LUD recruitment of ERCC1–GFP (top panel) 
or XPF–GFP (lower panel) and endogenous XPA in XPA-proficient 
and XPA KO U2OS cells, 1 h after 60 J/m2 UVC irradiation through 
an 8-µm microporous filter. Cells were immunostained against XPA 
and CPD, as damage marker. The GFP signal was not amplified using 
antibody staining. Scale bar: 5  µm. b Immunofluorescence images 
showing XPF–GFP LUD recruitment 1 h after 60 J/m2 UVC through 
an 8-µm microporous filter in XPA-proficient and XPA KO U2OS 
cells treated with nontargeting siRNA (sictrl) or siRNA targeting 
FANCD2 (siFANCD2). Cells were immunostained against GFP and 
CPD, which was used as damage marker. Scale bar: 5 µm. c Quanti-
fication of XPF–GFP LUD recruitment in XPA-proficient and XPA 
KO cells, as determined by immunofluorescence experiments shown 
in b. The fold accumulation at sites of local damage was calculated 
over the nuclear background and plotted as average of at least 100 
cells per condition from two independent experiments. Statistical sig-
nificant difference (p < 0.05) is indicated by asterisk, n.s. non-signifi-
cant. d Scatter plot of the  log2 SILAC ratio of the forward and reverse 
SILAC ERCC1–GFP immunoprecipitations experiments, comparing 
ERCC1–GFP interactors with and without UVC treatment (20 J/m2, 
1 h). UV-specific interactors are depicted in the upper right quadrant. 
In b error bars represent the SEM
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and XPF were clearly recruited to LUD in XPA-proficient 
cells, we could not observe clear recruitment in XPA KO 
cells. Depletion of FANCD2 in XPA-proficient and XPA 
KO cells expressing XPF–GFP, by a 48-h siRNA treatment 
(Fig. S1A), did not reduce XPF–GFP LUD recruitment as 
compared to control siRNA-treated cells (Fig. 2b, c). Our 
data confirm that ERCC1–XPF engagement in NER is 
completely dependent on XPA [45] and not regulated by 
FANCD2, indicating that the XPA KO cells can be used to 
study ERCC1–XPF activity outside NER.
To determine whether any additional, as-of-yet uni-
dentified factors regulate ERCC1–XPF recruitment to 
UV damage, we combined ERCC1–GFP immunoprecipi-
tation with stable isotope labeling by amino acids in cell 
culture (SILAC)-based quantitative proteomics (includ-
ing label swapping, i.e., “forward” and “reverse” replicate 
experiments). To this end, SILAC-labeled ERCC1–GFP-
expressing U2OS cells were mock-treated or exposed to 
UVC (20 J/m2) and 1 h after treatment chromatin-enriched 
nuclear extracts were subjected to GFP-mediated immu-
noprecipitation and mass spectrometry analysis. Interest-
ingly, and as expected, this showed that after UV irradia-
tion, ERCC1–XPF interacts with multiple components of 
the TFIIH complex, RPA and XPG (Fig. 2d and Table 1). 
Also XPA was identified as an interactor of ERCC1, but 
only in one of the replicate experiments and, therefore, not 
depicted in Fig. 2d. However, no additional new factors were 
identified, suggesting that no major or essential unknown 
factors exist that regulate ERCC1–XPF involvement in NER. 
Moreover, SLX4 was identified as a constitutive interaction 
partner of the endonuclease complex, in line with previous 
observations [2, 25, 26]. However, the interaction ratio of 
this partner did not change upon UV irradiation, in line with 
its specific role in ICLR.
ICLR and NER core factors localize 
to psoralen‑induced DNA damage
To analyze ERCC1–XPF recruitment to ICLs, we combined 
the use of the psoralen 8-methoxypsoralen (8-MOP) with 
UVA laser microirradiation along a user-defined track across 
the cell nucleus [44, 46], to activate the 8-MOP and induce 
local psoralen–DNA crosslinks. UVA activation of interca-
lated 8-MOP generates both monoadducts as well as ICLs 
in DNA [47–51]. The efficiency of this method to induce 
ICLs was shown by the clear recruitment of endogenous 
FANCD2 and SLX4 to local psoralen adducts, marked by 
γH2AX co-staining, as visualized by immunofluorescence 
in U2OS cells (Fig. 3a, 8-MOP + laser). Importantly, we did 
not observe recruitment of FANCD2 or SLX4 or induction 
of γH2AX in cells that were only UVA microirradiated but 
not treated with 8-MOP (laser), indicating that the applied 
UVA laser by itself did not generate DNA damage that leads 
to γH2AX signaling or is recognized by FANCD2. Further-
more, we observed clear recruitment of XPA to local pso-
ralen adducts, as marked by γH2AX (Fig. 3b), indicative of 
targeting of the core NER machinery to psoralen adducts 
and suggesting the induction of NER substrate lesions. As 
monoadducts formed by psoralen are known NER substrates 
[52, 53], XPA is likely recruited to psoralen monoadducts as 
part of the NER machinery. Since NER is also implicated in 
replication-dependent and -independent ICLR [31, 32], XPA 
may be recruited to psoralen-ICLs as well. Moreover, also 
endogenous XPF as well as ERCC1–GFP and XPF–GFP 
were clearly recruited to psoralen adducts. Because of the 
induction of multiple types of DNA damage, this accumula-
tion likely reflects the engagement of ERCC1–XPF in both 
active NER as well as ICLR.
ERCC1–XPF recruitment to psoralen adducts is XPA 
and FANCD2 dependent
To test whether ERCC1–XPF recruitment to ICLs is depend-
ent on FANCD2, we studied the recruitment of the complex 
to local psoralen adducts in ERCC1–GFP- and XPF–GFP-
expressing XPA-proficient and -KO cells, depleted of 
FANCD2 by siRNA (Fig.  4). In XPA-proficient cells, 
XPF–GFP recruitment to psoralen adducts was reduced 
after siFANCD2 treatment compared to control siRNA-
treated cells (Fig. 4a, b). Also, ERCC1–GFP recruitment 
was slightly reduced in siFANCD2-treated cells compared 
to control siRNA-treated cells (Fig. 4c, d). This was less 
pronounced than for XPF, possibly because of competition 
Table 1  UV-dependent ERCC1–GFP-interacting proteins identified 
by SILAC-MS
Unique peptides and normalized ratios of the forward and reverse 
experiments of the top interacting proteins with ERCC1 1  h after 
20  J/m2 UV irradiation. Also, peptides and ratios for ERCC1, XPF 
and SLX4 are shown
H heavy, L light
Protein names Unique 
peptides
Ratio H/L 
forward
Ratio L/H 
reverse
Average
XPB/ERCC3 18 22.991 20.10 21.55
XPD/ERCC2 24 11.55 19.57 15.56
p52/GTF2H4 8 8.0175 20.70 14.36
XPG/ERCC5 14 12.985 11.45 12.22
p34/GTF2H3 11 8.1806 17.08 12.63
p44/GTF2H2 13 7.2274 19.04 13.14
XPA 2 9.14 9.14
RPA1 7 4.8773 13.23 9.05
p62/GTF2H1 11 3.9822 12.33 8.15
XPF/ERCC4 51 1.9116 1.13 1.52
ERCC1 21 1.3952 0.93 1.16
SLX4 27 1.1329 0.72 0.93
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with endogenous ERCC1 that is still present in these cells 
(and which we did not visualize). These observations sug-
gest that ERCC1–XPF recruitment to psoralen adducts is 
partially dependent on FANCD2. Furthermore, the absence 
of XPA also induced a strong reduction in ERCC1–GFP 
and XPF–GFP localization to psoralen adducts that was fur-
ther reduced by additional FANCD2 depletion (Fig. 4). Our 
data, therefore, suggest that, in response to psoralen adducts, 
ERCC1–XPF is recruited both by XPA to participate in NER 
and by FANCD2 to function in ICLR. These observations in 
human cells are in accordance with chromatin immunopre-
cipitation (ChIP) studies in Xenopus egg extracts suggest-
ing that FANCD2 preceeds and is needed for ERCC1–XPF 
recruitment to an ICL [2].
The stronger reduction in ERCC1–XPF recruitment due 
to XPA KO as compared to siFANCD2 could be because of 
incomplete FANCD2 depletion by siRNA. However, con-
sidering that we obtained efficient FANCD2 knockdown 
(Fig. S1a) this is likely better explained by the observation 
that psoralen-ICLs are preferentially repaired via unhooking 
by the DNA glycosylase NEIL3, which is independent of 
FANCD2–FANCI [30]. Moreover, XPA, but not FANCD2, 
is implicated in replication-independent ICLR as well 
[31, 33, 35]. Knockout of XPA will, therefore, also impair 
ERCC1–XPF engagement in this pathway. Importantly, 
this implies that even though in our experiments we did not 
distinguish between different cell cycle phases of the cells 
under study (which were rapidly dividing U2OS cells), the 
FANCD2-dependent recruitment of ERCC1–XPF reflects 
its engagement in replication-dependent ICLR. Finally, we 
observed residual ERCC1–XPF recruitment even in the 
absence of both XPA and FANCD2. It is thus possible that 
the ERCC1–XPF complex can still be targeted to psoralen 
adducts, albeit less efficient, even in the absence of both of 
these factors. Alternatively, it could be that this residual tar-
geting reflects a function of the complex in yet another DNA 
repair pathway, possibly the repair of DSBs [5].
R689S and S786F mutant XPF recruitment 
to psoralen adducts is XPA dependent
Several of the XPF mutations reported in patients have been 
described to disrupt ICLR. Among these are C236R, located 
in the SF2 helicase-like domain and associated with XPCS 
complex with FA features [7]; R689S, located in the nucle-
ase domain and associated with FA [8]; S786F, also located 
in the nuclease domain and identified in a breast cancer [54]. 
Cells carrying the R689S or S786F mutant XPF alleles are 
hypersensitive to MMC but not to UV irradiation, suggest-
ing that the R689S and S786F mutations only impair XPF 
function in ICLR [8, 37, 54]. Conversely, C236R renders 
cells hypersensitive to both MMC and UV irradiation, indi-
cating that this mutation impairs XPF function in both ICLR 
and NER [7, 37]. Moreover, previous incision assays and 
Fig. 3  ICLR and NER core 
factors are recruited to 
psoralen-induced DNA dam-
age. a Immunofluorescence 
images showing recruitment 
of endogenous FANCD2 and 
SLX4 to sites of local UVA 
laser microirradiation in 
untreated (laser) or psoralen-
treated (8-MOP + laser, 50 µM 
8-MOP, 2 h) U2OS cells. Cells 
were immunostained against 
FANCD2, SLX4 and γH2AX, 
which was used as damage 
marker. Scale bar: 5 µm. b 
Immunofluorescence images 
showing recruitment to sites of 
local UVA laser microirradia-
tion in psoralen-treated U2OS 
cells (8-MOP + laser, 50 µM 
8-MOP, 2 h) of endogenous 
XPA and XPF (left panels) 
and in psoralen-treated U2OS 
cells expressing ERCC–GFP or 
XPF–GFP (right panels). Cells 
were immunostained against 
XPA, XPF, GFP and γH2AX, 
which was used as damage 
marker. Scale bar: 5 µm
 resaL resaL + POM-8
FANCD2 γH2AX DAPI FANCD2 γH2AX DAPI 
    
SLX4 γH2AX DAPI SLX4 γH2AX DAPI 
    
B
A
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ChIP experiments in Xenopus egg extracts showed that all 
three mutations impair the unhooking of a sequence-specific 
cisplatin–DNA ICL by XPF but not its recruitment to this 
lesion [55]. Therefore, we determined whether in human 
cells these mutations affect ERCC1–XPF recruitment to 
psoralen adducts.
We previously generated U2OS XPF KO cell lines that 
stably expressed GFP-tagged XPF mutants carrying the 
amino acid substitutions C236R (XPF–C236R), R689S 
(XPF–R689S) and S786F (XPF–S786F) [37]. To study 
their ability to be recruited to psoralen adducts repaired by 
NER or repaired by ICLR, we treated these cells with con-
trol, XPA and FANCD2 siRNA (Fig. S1a, B) and applied 
local UVA laser microirradiation after 8-MOP treatment. 
XPF–C236R was clearly recruited to sites of damage 
(Fig. 5a, b), which was reduced after FANCD2 and, even 
more, after XPA depletion. These results indicate that this 
XPF mutant is recruited to psoralen adducts as part of both 
the NER and the replication-dependent ICLR machin-
ery, similarly as wild-type XPF (Fig. 4a, b). Conversely, 
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Fig. 4  ERCC1–XPF recruitment to psoralen-induced DNA dam-
age is XPA and FANCD2 dependent. a Immunofluorescence images 
showing XPF–GFP recruitment to sites of local UVA laser microir-
radiation in psoralen-treated (50  µM 8-MOP, 2  h) XPA-proficient 
and XPA KO U2OS cells treated with nontargeting siRNA (sictrl) or 
siRNA targeting FANCD2 (siFANCD2). Cells were immunostained 
against GFP and γH2AX, which was used as damage marker. Scale 
bar: 5 µm. b Quantification of XPF–GFP recruitment to sites of local 
UVA laser microirradiation in psoralen-treated XPA-proficient and 
XPA KO U2OS cells, as determined by immunofluorescence exper-
iments shown in a. The fold accumulation at sites of local damage 
was calculated over the nuclear background and plotted as average of 
at least 80 cells per condition from three independent experiments. 
Statistically significant difference (p < 0.05) is indicated by aster-
isk. c Immunofluorescence images showing ERCC1–GFP recruit-
ment to sites of local UVA laser microirradiation in psoralen-treated 
(50 µM 8-MOP, 2 h) XPA-proficient and XPA KO U2OS cells treated 
with nontargeting siRNA (sictrl) or siRNA targeting FANCD2 
(siFANCD2). Cells were stained against GFP and γH2AX, which 
was used as damage marker. Scale bar: 5  µm. d Quantification of 
ERCC1–GFP recruitment to sites of local UVA laser microirradia-
tion in psoralen-treated XPA-proficient and XPA KO U2OS cells, as 
determined by immunofluorescence experiments shown in c. The fold 
accumulation at sites of local damage was calculated over the nuclear 
background and plotted as average of at least 100 cells per condition 
from two independent experiments. Statistically significant difference 
(p < 0.05) is indicated by asterisk. In b and d, error bars represent the 
SEM
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Fig. 5  R689S and S786F mutant XPF is recruited to psoralen adducts 
in an XPA-dependent and FANCD2-independent manner. a Immuno-
fluorescence images showing XPF recruitment to sites of local UVA 
laser microirradiation in psoralen-treated (50 µM 8-MOP, 2 h) U2OS 
XPF KO cells expressing GFP-tagged XPF carrying the amino acid 
mutations C236R, R689S or S786F, treated with nontargeting siRNA 
(sictrl) or siRNA targeting XPA (siXPA) or FANCD2 (siFANCD2). 
Cells were immunostained against GFP and γH2AX, which was 
used as damage marker. Scale bar: 5 µm. b Quantification of mutant 
XPF–GFP recruitment to sites of local UVA laser microirradiation in 
psoralen-treated U2OS XPF KO cells expressing GFP-tagged XPF 
carrying the amino acid mutations C236R, R689S or S786F, as deter-
mined by immunofluorescence experiments shown in a. The fold 
accumulation at sites of local damage was calculated over the nuclear 
background and plotted as average of at least 60 cells per condition 
from three independent experiments. Statistical significant difference 
(p < 0.05) compared to sicntrl of each cell line is indicated by aster-
isk. c Immunoblot analysis of cell lysate (input) and GFP immuno-
precipitation samples (elute) from wild-type U2OS cells (U2OS) and 
XPF KO U2OS cells expressing GFP-tagged wild-type XPF (XPF–
GFP) or XPF carrying the amino acid mutations R689S or S786F. 
Samples were analyzed with antibodies against GFP, ERCC1, SLX4, 
FANCD2, RPA70 and H2B (as loading control). Cells were mock 
treated (−) or incubated with 10 µg/ml MMC for 1 h before lysis. In 
the FANCD2 immunoblot, the asterisk indicates aspecific staining. In 
b error bars represent the SEM
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XPF–S786F and, even more so, XPF–R689S were recruited 
less efficiently to psoralen adducts. Strikingly, their recruit-
ment was only strongly reduced after XPA depletion but not 
significantly after FANCD2 depletion. This suggests that 
ERCC1–XPF carrying R689S or S786F can still be normally 
recruited as part of the NER machinery, in line with previ-
ous immunofluorescence and fluorescence recovery after 
photobleaching experiments that showed efficient binding 
of these mutants to UV-induced DNA damage [37]. How-
ever, the absence of a significant dependency on FANCD2 
suggests that these mutants cannot efficiently be recruited 
to or stably associate with psoralen–DNA ICLs, which is 
in line with the MMC hypersensitivity of cells expressing 
these mutants [8, 37, 54]. Interestingly, the less efficient 
recruitment to psoralen adducts of XPF–R689S compared 
to XPF–S786F may indicate that this mutation has a more 
deleterious effect on XPF function in ICLR. This is in line 
with the stronger MMC hypersensitivity observed in cells 
expressing XPF with this mutation [37] and the stronger 
nuclease and ICL-unhooking defect found with purified 
Xenopus XPF carrying this mutation [55].
In an effort to understand why XPF–R689S and 
XPF–S786F are inefficiently recruited, we tested whether 
these XPF mutants showed reduced interaction with 
known or hypothesized XPF-interacting proteins. To this 
end, we performed GFP immunoprecipitation experi-
ments on benzonase-treated lysate (i.e., to avoid isolation 
of DNA-mediated interactions/associations) from cells 
expressing GFP-tagged wild-type, R689S or S786F mutant 
XPF that was either mock treated or exposed to MMC. 
Importantly, we found that the mutant XPF proteins inter-
acted normally with ERCC1 (Fig. 5c), which is in line 
with previous observations that these mutants stabilize, 
and thus bind ERCC1 [8, 37, 55]. Moreover, treatment 
with the crosslinking agent MMC did not alter the ratio of 
the interaction between XPF and ERCC1. It is currently 
unclear through which protein interactions ERCC1–XPF 
is recruited to ICLs, except that this depends on binding to 
its partner SLX4 [2, 25, 26], which was suggested to inter-
act with mono-ubiquitylated FANCD2 [56]. Therefore, 
we tested whether these interactions were affected due to 
the XPF mutations. Strikingly, we did not observe any 
change in the interaction of XPF with SLX4, neither upon 
MMC exposure nor in the presence of the two XPF muta-
tions. Moreover, we were unable to co-immunoprecipitate 
FANCD2 with XPF, suggesting that these proteins do not 
interact directly. Because in vitro ERCC1–XPF activity 
in ICLR is stimulated by RPA [27, 57], we also tested 
whether RPA directly interacts with wild-type or R689S or 
S786F mutant XPF. However, GFP-tagged XPF was una-
ble to co-immunoprecipitate RPA70, the largest subunit of 
the heterotrimeric RPA complex, suggesting that stimula-
tion of XPF activity by RPA is not via a direct physical 
interaction between the proteins. In summary, it remains 
unclear how exactly ERCC1–XPF, in complex with SLX4, 
is recruited to ICLs and how specific mutations in XPF 
could affect this. We observed that, even in the presence 
of both FANCD2 and XPA, recruitment of XPF–S786F 
and XPF–R689S is impaired. It was previously proposed 
that R689S and S786F affect the positioning of the XPF 
nuclease domain around the ICL rather than the actual 
catalytic activity itself [55, 58]. It is, therefore, possible 
that this incorrect positioning impairs a stable association 
of ERCC1–XPF with DNA at the lesion site, leading to 
inefficient visual recruitment at ICL sites as observed in 
our immunofluorescence experiments.
Discussion
In this study, we show that in human cells, ERCC1–XPF 
is involved in the repair of the multiple types of lesions 
induced by psoralen–DNA crosslinking, as part of the NER 
machinery via XPA, and as part of replication-dependent 
ICLR via FANCD2. Our results highlight and help to bet-
ter understand the multifaceted activity and regulation of 
ERCC1–XPF in DNA repair, which is essential for a better 
comprehension of how the multiple DNA repair pathways 
in which ERCC1–XPF is involved tightly collaborate to pro-
tect against cancer and promote health. Moreover, our data 
encourage to seriously consider the activation of multiple 
DNA repair pathways when evaluating the (side) effects of 
using DNA crosslinking agents as therapeutic drugs.
It would be interesting to further investigate the kinetics 
of ERCC1–XPF recruitment to ICLs, to determine how this 
changes over time in accord with unhooking and repair of 
the lesions. Moreover, considering the different mechanisms 
involved in replication-dependent and replication-independ-
ent ICLR and the different activities that NER might have 
in both pathways, it would be useful to study the roles of 
ERCC1–XPF in these two different mechanisms by inves-
tigating how the complex is recruited to ICLs specifically 
in S-phase and non-S-phase cells. Additionally, the interac-
tion and interdependency of ERCC1–XPF with other ICLR, 
NER and HR factors should be determined in a cell cycle 
phase-specific manner, to precisely elucidate the multistep 
processes that lead to ICL removal. Possibly, ICLR factors 
that we did not investigate or unknown factors influence the 
recruitment of ERCC1–XPF and could help explain why 
the recruitment of XPF–R689S and XPF–S786F to ICLs is 
inefficient.
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